Ace Therapeutics
PrivateLast Round
Divestiture
May 6, 2026
Est. Valuation
$38M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Ace Therapeutics operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a VC Round in November 2015.
Ace Therapeutics is a biotechnology company that provides preclinical contract research services for drug discovery and development across various therapeutic areas.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ace Therapeutics Comparables
Compare Ace Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioDuro-Sundia | 82% | |
| Selvita | 81% | |
| Sygnature Discovery | 81% |
For institutional investors. Book with your work email.
Ace Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Divestiture | May 6, 2026 | ||||
| M&A | Jun 1, 2021 | ||||
| VC Round | Nov 6, 2015 |
For institutional investors. Book with your work email.
Ace Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lilly Asia Ventures | VC Round |
| Qiming Venture Partners | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 79% MoM.
- Jul 26, 2026
Monthly visitors increased 39% MoM, reaching 2.1K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 12, 2026
Ace Therapeutics launches an expanded suite of custom hypertension animal models in New York on Oct 13th '26, making customizable solutions available for studying hypertension, identifying therapeutic targets, and evaluating antihypertensive therapies.
- launchesAug 16, 2026
Ace Therapeutics unveils its full-spectrum respiratory infection model development service platform in New York on Aug 17th '26, offering customizable preclinical respiratory infection models with integrated PK/PD analysis for researchers developing therapeutics against pulmonary pathogens.
For institutional investors. Book with your work email.
Ace Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ace Therapeutics's valuation, stock price, and market status.
Is Ace Therapeutics a public or private company?
Ace Therapeutics is a private company.
What is the current stock price of Ace Therapeutics?
Ace Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ace Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ace Therapeutics worth (valuation)?
Ace Therapeutics's valuation is estimated at $38.0M based on funding round data.
Can I buy Ace Therapeutics stock?
Ace Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ace Therapeutics's last funding round?
Ace Therapeutics's most recent funding round was Divestiture on May 6, 2026.
Who are the main investors in Ace Therapeutics?
Key investors in Ace Therapeutics include Lilly Asia Ventures, Qiming Venture Partners.
Will Ace Therapeutics IPO soon?
No public IPO plans have been announced for Ace Therapeutics.
How can I track Ace Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ace Therapeutics's shares on secondary markets.